The U.S. Wanted Switzerland’s Drug Prices. Switzerland Is Starting to Lose Drug Launches.

On 13 August, Switzerland’s pharmaceutical industry published a statistic that deserves more attention than another routine access headline. Between January 2025 and June 2026, Interpharma members introduced 22 new innovative medicines, but only 15 were submitted for inclusion on Switzerland’s Specialties List, the route to broad reimbursement under mandatory health insurance. According to the association, seven were withheld because manufacturers feared that the resulting Swiss price could affect their U.S. business under America’s emerging Most-Favoured-Nation pricing policy. Three products were not submitted to Swissmedic for regulatory approval at all.

The numbers need caution. Interpharma represents industry, individual company decisions are not fully transparent, and Switzerland already had reimbursement delays long before MFN returned to the U.S. policy agenda. But the signal is still important. Across comparable 18-month periods between 2019 and 2025, an average of 24 medicines had been submitted for reimbursement. Now there were 15.

The obvious interpretation is that U.S. pricing policy may be delaying access in Switzerland. The more important conclusion is that the economic meaning of a Swiss price has changed. Once a reimbursement price negotiated for a relatively small European market can influence the economics of the largest pharmaceutical market in the world, the decision to launch in Switzerland is no longer simply a Swiss market access decision. It becomes part of global revenue protection.

Launch sequencing has always involved trade-offs. Companies weigh regulatory timing, patient numbers, HTA requirements, reimbursement probability, expected price, competitive dynamics and international reference pricing before deciding where to launch first. A small market may still be attractive if access is achievable and the commercial return justifies the effort.

MFN changes that calculation because it potentially changes what is at risk. If a company accepts a substantial discount in Switzerland and the consequence remains largely Swiss, the decision is familiar: sacrifice some price in exchange for reimbursement, volume and earlier patient access. But if that Swiss price can influence what the manufacturer earns in the United States, the local revenue gained may become trivial compared with the value placed at risk elsewhere.

That is the key shift. A market does not need to be large to become strategically dangerous. Its price only needs to travel.

This creates a new logic for global launch sequencing. Countries may increasingly be ranked not only by how attractive they are, but also by how risky it is to establish a visible reimbursed price there too early. A market can have high unmet need, supportive clinicians and a workable HTA pathway and still move down the launch sequence because the price required to secure reimbursement is considered globally unsafe.

It is tempting to describe delayed European launches as an unintended consequence of a U.S. policy designed to lower domestic drug prices. That framing is too simple.

The U.S. administration has repeatedly argued that American patients and taxpayers pay disproportionately high prices while other wealthy countries use stronger purchasing mechanisms to obtain the same medicines for less. MFN is therefore not only about importing lower international prices into the United States. It is also about challenging the global distribution of pharmaceutical revenues that produces those differences.

If manufacturers become less willing to accept low visible European prices because those prices could damage U.S. economics, that may not be a malfunction of the policy. It may be one of the ways the policy is expected to work.

For European payers, this changes the bargaining environment. The authority may retain exactly the same legal powers, the same HTA methodology and the same willingness to negotiate. What changes is the manufacturer’s willingness to enter the negotiation under the old terms.

A payer can reject a price. It cannot force a company to establish one.

That matters because access failure can now occur before HTA begins. The medicine does not need a negative recommendation, an unacceptable ICER or a failed price negotiation. The manufacturer may simply decide that entering the reimbursement process creates more global risk than local value.

The strongest counterargument is that Switzerland already had access problems. Reimbursement delays, growing use of individual-case funding and disagreements over manufacturer price expectations predate the current U.S. policy. Swiss authorities have also argued that companies sometimes submit later because the market is relatively small and that high price demands contribute to lengthy negotiations.

All of that is legitimate. MFN did not create every Swiss access problem, and it would be wrong to attribute every missing launch to Washington.

What may have changed is the marginal calculation. Existing Swiss pricing pressure now sits inside a much larger international risk architecture. A discount that was previously painful but acceptable can become unacceptable if it potentially affects U.S. revenues. MFN does not need to create the underlying friction to amplify its consequences.

The same logic applies even while the U.S. framework remains uncertain. Companies do not need perfect clarity before changing behaviour. If the downside is asymmetric, uncertainty alone can be enough.

Launching today captures some European revenue but creates a price that may later prove damaging. Waiting sacrifices near-term sales but preserves strategic optionality. If the concern proves exaggerated, the company has lost time and revenue. If the concern proves correct, launching too early could have consequences far beyond the market itself.

Those two errors do not have equal costs.

For global market access teams, this means cross-market exposure can no longer sit at the edge of the launch model. It increasingly belongs near the centre.

A local affiliate may present a compelling case based on unmet need, stakeholder readiness and expected national revenue and still lose the investment decision because headquarters sees a larger global price risk. The local team is optimising access to one country; the global organisation is protecting a worldwide price corridor.

The consequences can then spread beyond pricing. If reimbursement moves later, country-specific evidence generation may move with it. Payer engagement may be delayed. Early-access programmes may become more important. Regulatory sequencing itself may change where approval without a viable reimbursement strategy offers limited value.

A U.S. pricing policy can therefore propagate backwards through evidence planning, regulatory strategy and market access long before its effect becomes visible to patients.

There is also a likely response from both payers and manufacturers: greater reliance on confidential discounts and rebates. If visible prices become more dangerous because they can be referenced elsewhere, both sides gain an incentive to preserve the public list price while shifting the real economic concession into confidential arrangements. That creates a paradox: the more important international price comparison becomes, the stronger the incentive to make the relevant prices less observable.

The Swiss numbers are not proof that MFN is already restructuring global pharmaceutical launches. But they are an early signal of something more important than a change in list prices: a change in corporate behaviour before those prices ever exist.

That is what market access leaders should watch now. Not only how much countries pay, but which submissions never arrive, which markets quietly move down the launch sequence and where global teams increasingly decide that a locally acceptable price is no longer globally acceptable.

For years, the central lesson of market access has been that regulatory approval does not guarantee reimbursement, and reimbursement does not guarantee patient access.

MFN may be adding another layer.

The next access gap may begin before a payer assesses the evidence or negotiates a single euro of discount. It may begin with a global decision that the local price is simply too dangerous to create.

The United States wanted access to the prices negotiated by other wealthy countries. Switzerland may be showing the strategic response: when a national price becomes globally consequential, sometimes the safest price is the one that never appears.

Share

Beyond Approval publishes weekly strategic intelligence on market access, HTA, pricing, and regulatory shifts that reshape how medicines reach patients.